S2 Episode 6: Is MDMA a Potential Treatment for Negative Symptoms of Schizophrenia? Exploring Stigma and Strategies to Alleviate Symptoms

Medscape InDiscussion: Schizophrenia - A podcast by Medscape

Drs John M. Kane and Mitchell Arnovitz discuss assessment of patients for negative symptoms of schizophrenia and the potential of MDMA in alleviating these symptoms in supervised treatment settings. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/984490). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Schizophrenia https://emedicine.medscape.com/article/288259-overview MDMA for the Treatment of Negative Symptoms in Schizophrenia https://pubmed.ncbi.nlm.nih.gov/35743326/ MDMA (Ecstasy/Molly) https://nida.nih.gov/publications/drugfacts/mdma-ecstasymolly The NIMH-MATRICS Consensus Statement on Negative Symptoms https://pubmed.ncbi.nlm.nih.gov/16481659/ The Current Conceptualization of Negative Symptoms in Schizophrenia https://pubmed.ncbi.nlm.nih.gov/28127915/ Akinesia https://www.ncbi.nlm.nih.gov/books/NBK562177/ An Assessment of Five (PANSS, SAPS, SANS, NSA-16, CGI-SCH) Commonly Used Symptoms Rating Scales in Schizophrenia and Comparison to Newer Scales (CAINS, BNSS) https://pubmed.ncbi.nlm.nih.gov/29430333/ Ecological Momentary Assessment https://pubmed.ncbi.nlm.nih.gov/18509902/ Schizophrenia Medication https://emedicine.medscape.com/article/288259-medication#2 Cariprazine, a Broad-Spectrum Antipsychotic for the Treatment of Schizophrenia: Pharmacology, Efficacy, and Safety https://pubmed.ncbi.nlm.nih.gov/34091867/ DRD3 Dopamine Receptor D3 [Homo sapiens (human)] https://www.ncbi.nlm.nih.gov/gene/1814 MDA https://dictionary.apa.org/mda Transcranial Magnetic Stimulation: A Review of Its Evolution and Current Applications https://pubmed.ncbi.nlm.nih.gov/31359968/ Memantine https://www.ncbi.nlm.nih.gov/books/NBK500025/ Making MDMA a Medicine (II) (Re)scheduling for Schedule I Substances https://maps.org/news/bulletin/making-mdma-a-medicine-ii-rescheduling-for-schedule-1-substances/ Vesicular Monoamine Transporter 2 (VMAT2) Inhibitors https://www.ncbi.nlm.nih.gov/books/NBK548187/ Metaplasticity: Tuning Synapses and Networks for Plasticity https://pubmed.ncbi.nlm.nih.gov/18401345/ MDMA-Assisted Psychotherapy for Treatment of Posttraumatic Stress Disorder: A Systematic Review With Meta-Analysis https://pubmed.ncbi.nlm.nih.gov/34708874/ Reduction in Social Anxiety After MDMA-Assisted Psychotherapy With Autistic Adults: A Randomized, Double-Blind, Placebo-Controlled Pilot Study https://pubmed.ncbi.nlm.nih.gov/30196397/ Prefrontal Cortex-Nucleus Accumbens Interaction: In Vivo Modulation by Dopamine and Glutamate in the Prefrontal Cortex https://pubmed.ncbi.nlm.nih.gov/18508116/ Serotonin Syndrome https://emedicine.medscape.com/article/2500075-overview